Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity
PG Richardson, C Eng, J Kolesar… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Perifosine is a novel targeted oral Akt inhibitor currently in Phase III clinical
development for treatment of colorectal cancer (CRC, in combination with capecitabine) and …
development for treatment of colorectal cancer (CRC, in combination with capecitabine) and …
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
D Massihnia, A Avan, N Funel, M Maftouh… - Journal of Hematology & …, 2017 - Springer
Background There is increasing evidence of a constitutive activation of Akt in pancreatic
ductal adenocarcinoma (PDAC), associated with poor prognosis and chemoresistance …
ductal adenocarcinoma (PDAC), associated with poor prognosis and chemoresistance …
[HTML][HTML] Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells
CY Liu, CW Shiau, HY Kuo, HP Huang, MH Chen… - …, 2013 - ncbi.nlm.nih.gov
The multiple cellular targets affected by proteasome inhibition implicate a potential role for
bortezomib, a first-in-class proteasome inhibitor, in enhancing antitumor activities in …
bortezomib, a first-in-class proteasome inhibitor, in enhancing antitumor activities in …
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines
M Cosenza, M Civallero, S Pozzi… - Hematological …, 2015 - Wiley Online Library
We analyzed the combination of a proteasome inhibitor (bortezomib) with enzastaurin
(PKC/AKT‐inhibitor) or lenalidomide (immunomodulatory agent) for the inhibition of …
(PKC/AKT‐inhibitor) or lenalidomide (immunomodulatory agent) for the inhibition of …
Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model
DE Cole, CM Lester-McCully, BC Widemann… - Cancer chemotherapy …, 2015 - Springer
Purpose Central nervous system tumors are histologically and biologically heterogeneous.
Standard treatment for malignant tumors includes surgery, radiation and chemotherapy, yet …
Standard treatment for malignant tumors includes surgery, radiation and chemotherapy, yet …
Antitumour effect and modulation of expression of the ABCB1 gene by perifosine in canine lymphoid tumour cell lines
H Tomiyasu, Y Goto-Koshino, Y Fujino, K Ohno… - The Veterinary …, 2014 - Elsevier
Acquisition of multidrug resistance (MDR) is a common cause of treatment failure during
chemotherapy for dogs with lymphoma (lymphosarcoma). Overexpression of P-glycoprotein …
chemotherapy for dogs with lymphoma (lymphosarcoma). Overexpression of P-glycoprotein …
哌立福新增强胆管癌细胞化疗敏感性的实验研究
王保臣， 张弛， 孙伟， 孙跃明 - 中国现代医学杂志, 2011 - cqvip.com
目的研究哌立福新提高胆管癌细胞系Q BC 939 化疗敏感性的机制. 方法采用台盼蓝染色检测各
处理组的活细胞率, M TT 法检测细胞生长抑制率, 采用流式细胞仪以Annexin V 和7-AAD …
处理组的活细胞率, M TT 法检测细胞生长抑制率, 采用流式细胞仪以Annexin V 和7-AAD …
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors
M Schmidt-Hieber, R Dabrowski, B Aicher… - Investigational new …, 2012 - Springer
The novel AKT inhibitor perifosine possesses myelopoiesis-stimulating effects in rodents.
We studied the in vitro effects of the novel agents perifosine, bortezomib and lenalidomide in …
We studied the in vitro effects of the novel agents perifosine, bortezomib and lenalidomide in …
Experimental approaches in the treatment of multiple myeloma
SA Khan, AD Cohen - Therapeutic Advances in Hematology, 2011 - journals.sagepub.com
Myeloma therapy has undergone significant advances in recent years resulting in a marked
improvement in survival. Knowledge of the active pathways involved in myeloma …
improvement in survival. Knowledge of the active pathways involved in myeloma …
Perifosin ve D Vitamini kombinasyonunun endometriyum kanseri hücre hattı (HEC1A) üzerine etkisi
Mİ Karagül - acikbilim.yok.gov.tr
Endometriyum kanseri kadın üreme sisteminde en sık görülen kanserdir. Perifosin protein
kinaz B (AKT) fosforilasyonunu inhibe ederek çeşitli kanserlerde bir anti-kanser aktivitesi …
kinaz B (AKT) fosforilasyonunu inhibe ederek çeşitli kanserlerde bir anti-kanser aktivitesi …